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Abstract: The characteristics of non-obese patients with mild to 
moderate Obstructive Sleep Apnea Syndrome (OSAS) who will present 
with a good response to Mandibular Repositioning Appliance (MRA) 
treatment have not yet been well established in the literature. The aim of 
this study is to assess whether polysomnographic (PSG), demographic, 
anthropometric, cephalometric, and otorhinolaryngological parameters 
predict MRA success in the treatment of OSAS. Forty (40) males with 
mild and moderate OSAS were assessed pretreatment and 2-months 
post-treatment after wearing an MRA. Demographic, anthropometric, 
otorhinolaryngological (ENT), cephalometric, and polysomnographic 
parameters, including continuous positive airway pressure (CPAP) 
titrated pressure, dental models, Epworth Sleepiness Scale, quality of life 
(Short Form SF-36), and mood state (Profile of Mood States – POMS), were 
assessed. The responders exhibited fewer oropharyngeal alterations, 
increased upper pharyngeal space, reduced lower airway space, and 
increased mandibular intercanine width, and they had milder disease. 
Nevertheless, no predictive factors of MRA success could be found. MRA 
was more successful among men with a more pervious airway, a larger 
interdental width and milder OSAS. However, a combined [1] functional 
and structural assessment is needed to successfully predict the [2] 
effectiveness of MRA treatment of OSA.
Keywords: Polysomnography; Orthodontic Appliances; 
Otorhinolaryngologic Diseases; Cephalometry; Continuous Positive 
Airway Pressure.
Introduction
Obstructive sleep apnea syndrome (OSAS) is a highly prevalent 
sleep-related respiratory disorder characterized by a total or partial 
obstruction of the upper airways concomitant with respiratory effort 
during sleep, causing intermittent hypoxemia and sleep fragmentation.1 
In the first studies, the prevalence of OSAS — defined by an 
apnea-hypopnea index (AHI) greater than five events per hour — was 
estimated to be between 6.5% and 9% in women and between 17% and 
31% in men.2 However, this prevalence has since been revised to be 
approximately 34% in men aged 30–70 years and 17% in women aged 30–70 
years.3 In a study from Brazil with 1042 participants aged 20–80 years, 
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the researchers reported a higher prevalence 
(AHI > 5) of 46.6% in men and 30.5% in women.4 
A population-based study in Switzerland reported 
that the prevalence of moderate-to-severe OSAS 
(AHI ≥ 15) was 23.4% in women and 49.7% in men.5 
Obesity, male gender, age and craniofacial alterations 
are the principal risk factors. In addition to the high 
prevalence, this disorder has health consequences 
such as cardiovascular and metabolic diseases, 
automobilist crash risk and higher mortality rate.6
Continuous Positive Airway Pressure (CPAP) 
is the gold standard for OSAS treatment. However, 
tolerance and treatment adherence are low, which 
reduces the effectiveness. The use of a Mandibular 
Repositioning Appliance (MRA) is indicated in 
patients with a primary snore, mild OSAS or who 
are CPAP intolerant.7 Despite the low MRA rate of 
success of 48%,8 important health outcomes were 
similar after 1 month of optimal MRA and CPAP 
treatment in patients with moderate severe OSAS. 
The results may be explained by the greater efficacy 
of CPAP being offset by inferior compliance relative 
to MRA, resulting in similar effectiveness.9
However, the inability to predict which patients 
will respond well to the treatment limits the clinical 
use of an MRA.10 The construction of a custom-made 
device for each patient and a titration period for the 
mandible to adapt demands time and money.11 Factors 
such as a younger age, lower body mass index (BMI), 
smaller neck circumference, female gender, lower 
AHI (apnea-hypopnea index), increased amount of 
mandibular advancement, and the need for CPAP 
pressure lower than 10.5 cm H2O were postulated as 
predictors of short-term success.11,12,13,14 Studies have 
evaluated cephalometric parameters, spirometer 
results, drug-induced sleep endoscopy, remotely 
controlled mandibular positioners, multisensory 
catheter parameters and dental model analysis to 
predict the success of OSAS treatment using an 
MRA.14,15,16,17,18,19,20,21,22,23. In spite of obtaining good 
results, studies that evaluate the remotely controlled 
mandibular positioner and drug-induced sleep 
endoscopy are very difficult to execute.8
To predict the success of the MRA, it is fundamental 
that Polysomnography (PSG) be used with accurate 
criteria sucess. The predictor must be simple, not 
invasive and easily accessible.8 Therefore, the aim 
of the present study was to assess in a prospective 
study whether demographic, anthropometric, Ear, 
Nose and Throat evaluation (ENT), cephalometric, 
and PSG factors, including CPAP titration pressure 
and an analysis of dental models, might predict the 
success of MRA in the treatment of OSAS in non-obese, 
non-severe, male patients.
Methodology
Men aged 25 to 65 years old with a BMI of 
≤ 30 kg/m2 and OSAS24 were selected in the outpatient 
sleep clinic at Unifesp, Brazil. The exclusion criteria were 
decompensated clinical morbidities, sleep disorders, 
alcoholism, the use of sleep inducers, and sleep 
deprivation. Other criteria included intolerance to the 
use of CPAP on the titration night, previous treatment for 
OSAS, dental alterations hindering the use of an MRA 
such as less than 10 teeth per dental arch, periodontal 
and dental problems, severe temporomandibular 
disorders, and a maximum mandibular protrusion 
of less than 4 mm. The protocol was approved by the 
research ethics committee of the Unifesp (0352/09) and 
was registered at ClinicalTrials.gov (NCT01336556). The 
participants signed informed consent forms. The study 
protocol is presented in Figure 1.
Full night complete PSG was performed in a lab 
(EMBLA® S7000, Embla Systems, Inc., Broomfield, 
USA). Sleep staging was performed according to 
the Restchafen and Kales’ criteria,25 and events were 
scored according to the American Academy of Sleep 
Medicine criteria (AASM).26 OSAS severity was 
classified according to AASM criteria.27 CPAP devices 
(REMstar® Plus; Respironics Inc., Murrysville, PA) 
with a nasal mask were used. The CPAP titration was 
manually performed per guidelines.28 The analyzed 
anthropometric measures were BMI and neck 
circumference. The ENT assessment was performed 
according to Zonato et al.29 (Table 1). Lateral tele 
radiographs were acquired with a Vatech – PaX 400 
device, and Radioed Studio software was used to 
generate the cephalometric analysis (the mandibular 
and maxillary position in relation to the cranium, the 
length and flexion of the cranium base, the length 
of the mandibular and maxilla, the hiode position, 
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the superior and medium pharyngeal space and 
the length and width of the soft palate) (Figure 2). 
Dental models were used for linear measurements of 
the oral cavity size. The following measurements were 
performed using a dry-tip compass: intercanine width, 
interpremolar width, intermolar width, maxillary and 
mandibular lengths, palate height and mouth floor 
depth. All the patients responded to questionnaires 
before and after treatment: the Epworth Sleepiness 
Scale (ESS),30 the Short Form Health Survey (SF-36)31 
and the Profile of Mood State (POMS).32 
The Brazilian Dental Appliance (BRD) MRA, 
individualized, in acrylic, with two plaques allowing 
a progressive advance, was used.33 The initial position 
was set as 50% of the maximum protrusion followed by 
1 mm advancements every 7 days until the maximum 
comfortable protrusion or the maximum protrusion 
recorded at the initial assessment was achieved. The 
individuals who achieved an AHI with an MRA 
of < 5 associated with a reduction of at least 50% of 
the baseline AHI were considered responders.20,34
Statistical analyses were performed with SPSS 
version 18 software. The normality of data was assessed 
with the Kolmogorov-Smirnov test. To compare the 
variables before and after treatment, a paired Student’s 
t-test or a Wilcoxon test was used. The comparison of 
variables between the responders and non-responders 
before and after treatment was performed using the 
chi-square test, a Mann-Whitney test or Student’s t-test. 
Receiver operating characteristic curves (ROCs) were 
Table 1. Evaluation ENT. 
Craniofacial 
alteration
2 of the 
following
Angle class II malocclusion
retrognathic facial profile
Ogival palate
Unfavorable 
nose
1 of the 
following
Septum deviation grade II or III
Turbinate hypertrophy + rhinitis or 
obstruction of complaint nose
Septum deviation grade I + rhinitis 
or obstruction of complaint nose
Unfavorable 
oropharynx
3 of the 
following
Palate WeB
More posterior or tick palate
Long or thick uvula
Medial pillars
Tonsils grade III or IV
Unfavorable 
mallampati
Class III or IV
Treatment MRA 2 months
Pos-treatment Questionaries
Final polysomnography with MRA
Elaboration and progressive ajustment of the MRA
Pre-treatment Questionaries
ENT + dental + orthodontic assessment
Outpatient clinic of sleep-related respiratory disorders
Sleep Medicine and Biology
Baseline polysomnography
20 Patient Mild OSA 
(5≤IAH<15)
20 Patient MOD OSA 
(15≤IAH<30)
Figure 1.  Study protocol.
VASP
VAIP VAIA
VASA
Figure 2. Schematic lateral cephalogram illustrating the 
upper pharyngeal space (VASP–VASA) and lower airway space 
(VAIP–VAIA).
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elaborated to establish cut-off points predictive of 
success for the continuous variables. Logistic regression 
was performed using new variables categorized by 
means of the ROC curve to identify the variables that 
most influenced success. The ∆ percentage of the pre- 
and post-treatment AHIs was also calculated and 
used as a dependent variable in the linear regression 
analysis. In all analyses, the level of significance was 
established as 0.05, i.e., p ≤ 0.05.
Results
Forty-three (43) patients were selected, among 
which one (1) was not able to use the MRA and two 
(2) did not return for the final PSG.
Participants’ initial characteristics and responses 
to treatment are presented in Table 2 and 3. The final 
sample comprised 40 men, 20 with mild OSAS and 
20 with moderate OSAS, 65% of whom responded 
to treatment (p = 0.05). The objective assessment of 
sleep by means of the PSG shows that MRA treatment 
induced a significant reduction in the AHI (p = 0.000), 
and 85% of the participants exhibited a reduction of 
at least 50% of the baseline AHI.
The individuals with mild OSAS exhibited a greater 
response to treatment compared to the individuals 
with moderate OSAS (p = 0.05), although the baseline 
AHI and the CPAP titration pressure did not differ 
(p = 0.314 and p = 0.091, respectively). An analysis of 
the changes in the PSG parameters in the responders 
Table 2. All patients (n = 40) - Pre- and post-treatment data.
Variables
Pre-treatment Post-treatment
(95%CI/SE) (95%CI/SE)
BMI (kg/m2) (24.0–27.8) / 0.9 (24.3–28.0) / 0.9
AHI (events/hour) (12.0–18.1) / 1.5 (2.1–8.1) / 1.4*
Sleep onset latency (min) (5.0–10.5) / 1.3 (4.3–20.7) / 3.9
Total sleep time (min) (350.2–405.3) / 13.2 (339.1–390.9) / 12.3*
Sleep efficiency (%) (78.5–88.6) / 2.4 (79.4–89.6) / 2.4*
Arousal index (15.0–21.9) / 1.6 (9.4–14.7) / 1.3*
Baseline SaO2 (94.8–96) / 0.3 (95.0–96.2) / 0.3
Mean SaO2 (94.2–95.5) / 0.3 (94.4–95.7) / 0.3
Min SaO2 (86.8–89.4) / 0.62 (88.7–91.5) / 0.7*
Epworth (9.8–15.1) / 1.25 (5.1–9. 9) / 1.1
POMS
Tension (7.4–12.6) / 1.2 (5.2–10.9) / 1.4
Depression (4.2–11.1) / 1.6 (3.7–11.3) / 1.8
Anger (5.2–12.7) / 1.8 (3.8–11.4) / 1.8
Fatigue (8.0–12.6) / 1.1 (4.0–9.6) / 1.3
Vigor (13.8–18.0) / 1.0 (14.2–20.1) / 1.4
Confusion (5.0–8.4) / 0.8 (1.4–6.1) / 1.3
Total score (15.4–40.1) / 5.9 (1.3–30.2) / 6.9
SF-36
Physical functioning (66.8–89.0) / 5.3 (84.3–97.3) / 3.1
Limitation physical features (51.3–82.1) / 7.4 (73.4–95.0) / 5.1
Pain (59.1–78.9) / 4.7 (68.4–90.4) / 5.2
General health (63.8–9.8) / 3.8 (71.5–86.2) / 3.8
Vitality (46.2–63.8) / 4.2 (57.7–75.0) / 4.1
General features (71.0–90.9) / 4.8 (70.6–91.2) / 4.9
Limitation emotional features (63.8–94.9) / 7.4 (56.3–91.1) / 4.2
Mental health (57.7–74.9) / 4.1 (64.1–81.6) / 4.2
BMI: body mass index; AHI: apnea/hypopnea index. Data presented as confidence intervals (CIs) and standard errors of the mean (SEs) paired 
Student’s t-test and the Wilcoxon test; *p > 0.05
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and non–responders for the pre– and post–treatment 
periods showed that although the ∆ AHI was greater 
in the responders, the difference was not significant 
(p = 0.07). Conversely, the ∆ of the average saturation 
was significantly greater in the responders (p = 0.011).
 The parameters of age, BMI, and neck circumference 
did not exhibit significant differences between the 
responders and non–responders. Individuals with 
pharyngeal alterations exhibited less response to this 
therapeutic modality (p < 0.05) (Table 4). 
When cephalometric variables were analyzed, 
the responders exhibited a significantly larger upper 
pharyngeal space (p = 0.032) and smaller lower airway 
space (p = 0.042) (Figure 2). The analysis of interdental 
measures demonstrated that the responders had 
increased lower intercanine width compared to the 
non–responders (p = 0.029).
The ESS score was similar at baseline but showed a 
significantly greater improvement in responders when 
compared to non–responders (p = 0.05). The POMS and 
SF–36 parameters did not exhibit significant differences 
between those groups before and after treatment.
ROC curves for the continuous variables that 
exhibited statistically significant values between 
Table 3. Responders and non-responders - Pre- and post-treatment data.
Variables
Responders (n = 26) Non-responders (n = 14)
Pre-treatment Post-treatment Pre-treatment Post-treatment
(95%CI/SE) (95%CI/SE) (95%CI/SE) (95%CI/SE)
BMI (kg/m2) (24.0–27.8) / 0.9 (24.3– 28.0) / 0.9   
AHI (events/hour) (9.9–17.2) / 1.7 (1.7– 3.1) / 0.3* (11.4–23.8) / 2.6 (2.6–17.3) / 3.0*
Sleep onset latency (min) (3.5–8.6) /1.2 (2.4–20.4) / 4.1 (4.1–16.9) / 2.7 (–6.0–35.0) / 8.4
Total sleep time (min) (332.4–411.6) / 18.2 (346.2–402.8) / 12.8* (341.7–432.5) / 19.2 (286.5–411.1) / 25.5
Sleep efficiency (%) (75.5–89.6) / 3.2 (79.1–90.1) / 2.5* (76.4–94.1)–3.8 (71.2–97.2) / 5.3
Arousal index (13.2–24.0) / 2.5 (8.7–16.1) /1.7* (14.3–22.1) / 1.6 (6.6–6.6) / 2.0
Baseline SaO2 (94.5–95.8) / 0.3 (95.0–96.1) / 0.3 (94.7–97.1) / 0.5 (93.9–97.3) / 0.7
Mean SaO2 (93.9–95.3) / 0.3 (94.5–95.7) / 0.3 (93.6–96.8) / 0.7 (93.2–96.6) / 0.7
Min SaO2 (86.1–89.2) / 0.7 (89.8–92.0) / 0.5* (86.0–91.5) / 1.2 (85.0–92.4) / 1.5
Epworth (12–17) / 1 (2.6–6.6) / 0.8* (4.30–14.0) / 2.0 (5.8–12.6) / 1.6*
POMS
Tension (7.7–14.4) /1.5 (5.2–13.6) / 1.9* (3.4–13.3) / 2.1 (2.3–9.2) / 1.4
Depression (4.4–13.2) / 2.0 (3.1–13.9) / 2.4 (-0.9–12.6) / 2.9 (-0.6–12.3) / 2.7
Anger (5.2–12.5) / 1.7 (3.3–14.3) / 2.5 (-0.5–18.7) / 4.1 (-0.4–11.3) / 2.4
Fatigue (7.5–14.5) / 1.6 (2.7–11.1) /1.9* (6.0–12.3) / 1.3 (2.5–11.0) / 1.7
Vigor (12.6–18.3) /1.3 (14.6–21.4) / 1.6 (12.6–20.7) / 1.7 (8.8–22.6) / 2.8
Confusion (4.5–9.5) / 1.2 (0.7–7.5) /1.6* (3.5–9.0) / 1.2 (-0.8 7.1) / 1.6
Total Score (16.0–46.5) / 7.0 (–1.1– 40.6) / 9.5 (-3.7–47.9) / 10.9 (-14.2–32.2) / 9.5
SF–36
Physical functioning (61.5–92.4) 7.1 (84.8–100.2) / 3.5 (59.3–99.4) / 8.5 (73.0–102.7) / 6.1
Limitation physical features (50.8–91.5) / 9.3 (69.2–97.4) / 6.4 (23.0–88.8) / 12.4 (63.2–108.3) / 9.2
Pain (52.3–79.2) / 6.2 (65.1–96.2) / 7.0* (56.4–91.8) / 7.5 (57.3–97.0) / 8.1
General health (65.2–82.7) / 4.0 (72.7–87.0) / 3.2 (49.6–87.1) / 7.9 (57.4–96.9) / 8.1
Vitality (41.2–66.5) / 5.8 (56.7–75.8) / 4.4* (42.2–71.5) / 6.2 (44.8–88.1) / 8.8
General features (68.4–95.0) / 6.1 (64.2–94.0) / 6.8 (60.4–99.0) / 8.2 (66.6–101.2) / 7.1
Limitation emotional features (65.1–104.1) / 8.9 (41.1–92.2) / 11.6 (39.4–102.2) / 13.3 (61.4–110.0) / 9.9
Mental health (50.2–74.7) / 5.6 (56–78.7) / 5.2 (59.7–85.3) / 5.4 (67.8–96.8) / 5.9
BMI: body mass index; AHI: apnea/hypopnea index. Data are presented as confidence intervals (CIs) and standard errors of the mean (SEs); 
Mann–Whitney and Student’s t–tests;*p > 0.05.
Table 4. ENT parameters for the responders and non–responders.
ENT Parameters x2 p
Craniofacial alterations 1.50 0.16
Pharyngeal alterations 3.57 0.05*
Evident nasal alteration 0.81 0.25
Modified Mallampati score 0.01 0.56
Chi square ; *p > 0.05
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responders and non–responders were generated. 
The variables included lower airway space, upper 
pharyngeal space, and lower intercanine width. Larger 
area under the curves (AUCs) and significant p–values 
were found for upper pharyngeal space (AUC = 0.707 
and p = 0.032) and lower pharyngeal space (AUC = 0.691 
and p = 0.049). The intercanine distance showed an AUC 
of 0,257. When the proposed literature cut–off value 
was used, a CPAP of 10,5 cm H2O, the AUC was 0.377.
Univariate and multivariate logistic regression 
was performed using the selected criterion of success 
adopted as a dependent variable. However, this 
analysis did not allow the selection of any variable. 
Next, we performed a multivariate linear regression 
analysis using the ∆ percentage of AHI before and 
after treatment as the dependent variable for all of the 
variables analyzed. However, we were once again not 
able to identify any variable that was able to predict 
the success of OSAS treatment using an MRA.
Discussion
The present study assessed demographic, 
anthropometric, and PSG parameters, including CPAP 
titration pressure, ENT alterations, cephalometric 
parameters, and dental model analysis as possible 
predictors of the success of an OSAS treatment using 
an MRA in a prospective study. In our non–obese 
population, fewer factors appeared to influence the 
prediction of treatment outcomes.
Our results show that treatment success in 
non–obese, non–severe OSA patients with an MRA 
was greater among patients with milder OSAS, an 
absence of pharyngeal alterations, increased upper 
pharyngeal space, reduced lower airway space, 
increased mandibular intercanine width, and a greater 
reduction in sleepiness following treatment. However, 
none of these factors were predictive of the response 
to the MRA when plotted in a regression an analysis.
The reported efficacy of OSAS treatments using an 
MRA regarding AHI, arousal index, post–treatment 
minimum oxygen saturation, excessive daytime 
sleepiness and quality of life indices was also observed 
in the present study.35,36
Even though studies show that the response to 
treatment presents an inverted correlation to basal AHI14 
and we have observed that patients with mild OSAS had 
a better response to treatment, significant differences 
between the responders and non–responders were 
absent. The observed success rate was 65% percent, 
which corroborated with other studies that also dealt 
with individuals with severe OSAS, suggesting that 
the success of treatment of OSAS with the use of MRA 
might not depend on severity and might be more 
related to the nature of a multi factorial disease.37,38
Otsuka et al.39 assessed the effect of craniofacial 
traits on the success of MRA treatment and controlled 
for the baseline AHI because they considered it 
a possible confounding factor in the response to 
treatment. In that study, the individuals who responded 
to the treatment exhibited an increased pharyngeal 
cross–sectional area and increased middle and lower 
airway space. In our study, the pretreatment AHI did 
not differ between the responders and non–responders, 
and these variables did not influence the model and 
showed no prediction influences. In contrast, the 
responders in our sample exhibited a reduction in 
the lower airway space.
Some authors reported13,14,17 that an MRA is more 
effective among individuals who exhibit the greatest 
number of respiratory events in the supine position, 
which was not found in our study. Because we did 
not include patients with severe OSAS or increased 
BMI, as the abovementioned studies did, other factors, 
such as the craniofacial conformation, may have 
exerted a greater influence on the results. Tsuiki et al.20 
performed a retrospective study with patients with 
OSAS and an AHI of > 5 who were already using CPAP 
with good adherence to the treatment. They showed 
that the individuals subjected to therapeutic CPAP 
pressures of ≤ 10.5 cm H2O exhibited a satisfactory 
response to treatment with an MRA, which was 
different from the patients who required higher CPAP 
pressures. In the present study, we were not able to 
identify a possible cut–off point for CPAP pressure 
to predict therapeutic success.
Although Tsuiki et al.20 applied the same success 
criteria and the mean BMI of their sample was similar 
to ours, they assessed a Japanese population, which 
could mean that for their population the AHI were 
higher than in our study, which comprised a Brazilian 
population, which is known to be ethnically mixed.40 
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Bosoglu et al.41 asserted that race and ethnicity might 
be important determinants of body traits, the severity 
of OSAS, and effective CPAP pressures. Therefore, 
racial differences might account for the differences 
among the results observed.
The success of OSAS treatment with an MRA 
is greater among females compared to males.14 
We have included only male subjects, since gender 
was identified as a possible confounding factor 
in the response to OSAS treatment with an MRA, 
as stated by other authors.39 This exclusion represents 
a limitation of the present study, as the results cannot 
be extended to women with OSAS.
Some studies indicated that younger patients 
exhibited a better response to an MRA.13,23,38 In our 
study, age was not an influential factor for treatment 
success. Our study is similar to the studies by 
Tsuiki et al.20 and Zeng et al.,35 in which age did 
not correlate with the response to treatment, which 
is most likely because we established a rigorous 
criterion of success.
Although BMI and neck circumference are 
mentioned as possible predictors of the success 
of treatment with an MRA,38 in the present study, 
in which obese patients were excluded, BMI did 
not exert a significant influence on the success of 
treatment. This finding might be explained by the 
fact that our patients’ BMIs were not too high or by 
the rigorous criterion of success that we applied.13,20,37.
No significant difference in the amount of 
mandibular advancement was found in our study 
between the responders and non–responders, 
which corroborates the results of Mostafiz et al.23 
An increase in the elasticity of the tongue’s soft 
tissue might limit the mechanical transmission of 
the mandibular advancement force to the base of 
the tongue.39,42
In agreement with the findings by Liu et al.10 and 
Otsuka et al.,39 we also found a reduction in the lower 
airway space in the responders. Individuals with a 
narrowing of the upper airways exhibited a greater 
tendency for collapse; thus, we may postulate that 
a volumetric increase in this area induced by an 
MRA, even in an upper location, might contribute 
to a reduction in the airway collapsibility, thereby 
promoting treatment success.
Regarding the increase in the upper pharyngeal 
space, we were not able to identify any study that 
employed cephalometry that correlated a specific 
variable with the success of an MRA for OSAS 
treatment.43,44 This result was corroborated by our ENT 
findings because the individuals without pharyngeal 
alterations, with a wider pharynx, also exhibited 
a better response to treatment. The remainder of 
the ENT parameters analyzed in the present study 
did not exhibit significant differences between the 
responders and non–responders.
Upon assessing linear measures in dental models, 
Mostafiz et al.23 did not find a significant difference 
between the responders and non–responders. 
Nevertheless, the authors observed a correlation 
between a larger upper intermolar width and a 
greater reduction of AHI when comparing the pre– 
and post–treatment periods. The same analysis 
was performed in the present study, and it was 
observed that the responders exhibited a greater 
lower intercanine width. Although the mechanisms 
by which an MRA is beneficial to OSAS are not 
clearly understood, increases in the upper airway 
dimensions and the craniofacial structure appear 
to play an important role.23,45
No variables that influenced the success of 
OSAS treatment with an MRA were identified 
based on a logistic regression analysis using the 
selected criterion of success as a dependent variable. 
In addition, no variables were identified by a 
linear regression analysis to be predictive of the 
percentage variation of the AHI before and after 
treatment with an MRA. We believe that this lack 
of predictive value of the variables might be due to 
the multifactorial nature of the response to OSAS 
treatment. Nevertheless, these findings represent 
an important contribution to the understanding 
of the mechanisms that underlie the efficacy of an 
MRA in OSAS treatment.
Some limitations of our study should be cited; 
the power analysis of our sample size and effect size 
was low, which may reflect a low number of patients 
included, and the inclusion criteria of only non–obese 
men could restrict our results for this population.
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Conclusion
Our results show that the treatment success 
in non–obese, non–severe OSAS patients with an 
MRA was greater among the patients with milder 
OSAS, an absence of pharyngeal alterations, 
increased upper pharyngeal space, reduced lower 
airway space, increased mandibular intercanine 
width, and a greater reduction of sleepiness 
following treatment.
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